Evidence map›Paper›PMID 39664414›Full record

ReviewActa pharmaceutica Sinica. B2024

Strategies for intravesical drug delivery: From bladder physiological barriers and potential transport mechanisms.

Zheng-An Li, Kai-Chao Wen, Ji-Heng Liu, Chuan Zhang, Feng Zhang, Feng-Qian Li

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zheng-An LiSchool of Medicine, Shanghai University, Shanghai 200444, China.
Kai-Chao WenSchool of Medicine, Shanghai University, Shanghai 200444, China.
Ji-Heng LiuDepartment of Urology/Pharmaceutics, Shanghai Eighth People's Hospital, Shanghai 200235, China.
Chuan ZhangSchool of Medicine, Shanghai University, Shanghai 200444, China.
Feng ZhangDepartment of Urology/Pharmaceutics, Shanghai Eighth People's Hospital, Shanghai 200235, China.
Feng-Qian LiSchool of Medicine, Shanghai University, Shanghai 200444, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravesical drug delivery (IDD), as a noninvasive, local pathway of administration, has great clinical significance for bladder diseases, especially bladder cancer. Despite the many advantages of IDD such as enhanced focal drug exposure and avoidance of systemic adverse drug reactions, the effectiveness of drug delivery is greatly challenged by the physiological barriers of the bladder. In this review, the routes and barriers encountered in IDD are first discussed, and attention is paid to the potential internal/mucosal retention and absorption-transport mechanisms of drugs. On this basis, the avoidance, overcoming and utilization of the "three barriers" is further emphasized, and current design and fabrication strategies for intravesical drug delivery systems (IDDSs) are described mainly from the perspectives of constructing drug reservoirs, enhancing permeability and targeting, with the hope of providing systematic understanding and inspirations for the research of novel IDDSs and their treatment of bladder diseases.

Indexed as

BladderBladder cancerCarrier designDelivery mechanismIntravesical drug deliveryIntravesical therapyPenetrationTransport barrier

Identifiers

PMID39664414
PMCPMC11628814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.